

WHAT IS CLAIMED IS:

1. A crystalline Form IV {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone characterized by a solid-state ^{13}C nuclear magnetic resonance spectrum comprising peaks at the following chemical shifts: 52.3 ± 0.2 and 195.4 ± 0.2 ppm.

2. The crystalline Form IV of **Claim 1** characterized by a solid-state ^{13}C nuclear magnetic resonance spectrum further comprising peaks at the following chemical shifts: 123.5 ± 0.2 , 127.2 ± 0.2 , 131.4 ± 0.2 , 133.5 ± 0.2 , 136.9 ± 0.2 , 146.7 ± 0.2 , 149.3 ± 0.2 , and 151.4 ± 0.2 ppm.

3. The crystalline Form IV of **Claim 2** characterized by a solid-state ^{13}C nuclear magnetic resonance spectrum further comprising peaks at the following chemical shifts: 129.6 ± 0.2 and 135.4 ± 0.2 ppm.

4. The crystalline Form IV of any of **Claims 1 to 3** characterized by an X-ray powder diffraction pattern comprising at least one peak, which peak is at $12.1 \pm 0.1^\circ$ in 2θ .

5. The crystalline Form IV of any of **Claims 1 to 3** characterized by an X-ray powder diffraction pattern comprising at least two peaks wherein one peak is $12.1 \pm 0.1^\circ$, and the second peak is selected from the group consisting of $8.3 \pm 0.1^\circ$, $14.3 \pm 0.1^\circ$, $16.6 \pm 0.1^\circ$, $16.9 \pm 0.1^\circ$, and $18.5 \pm 0.1^\circ$ in 2θ .

6. The crystalline Form IV of any of **Claims 1 to 3** characterized by an X-ray powder diffraction pattern comprising at least the following peaks: $8.3 \pm 0.1^\circ$, $12.1 \pm 0.1^\circ$, $16.6 \pm 0.1^\circ$, $16.9 \pm 0.1^\circ$, and $18.5 \pm 0.1^\circ$ in 2θ .

7. The crystalline Form IV of any of **Claims 1 to 3** characterized by an X-ray powder diffraction pattern comprising at least the following peaks: $7.7 \pm 0.1^\circ$, $8.3 \pm 0.1^\circ$, $12.1 \pm 0.1^\circ$, $12.7 \pm 0.1^\circ$, $13.5 \pm 0.1^\circ$, $14.3 \pm 0.1^\circ$, $14.9 \pm 0.1^\circ$, $16.6 \pm 0.1^\circ$, $16.9 \pm 0.1^\circ$, $18.5 \pm 0.1^\circ$, $21.9 \pm 0.1^\circ$, and $24.9 \pm 0.1^\circ$ in 2θ .

8. A crystalline Form V {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone characterized by a solid-state ^{13}C nuclear magnetic resonance spectrum comprising peaks at the following chemical shifts: 54.3 ± 0.2 and 196.6 ± 0.2 ppm.

9. The crystalline Form V of **Claim 8** characterized by a solid-state ^{13}C nuclear magnetic resonance spectrum further comprising peaks at the following chemical shifts: 123.7 ± 0.2 , 127.4 ± 0.2 , 132.0 ± 0.2 , 134.3 ± 0.2 , 137.1 ± 0.2 , 145.8 ± 0.2 , and 151.0 ± 0.2 ppm.

5 10. The crystalline Form V of **Claim 9** characterized by a solid-state ^{13}C nuclear magnetic resonance spectrum further comprising peaks at the following chemical shifts: 130.1 ± 0.2 and 149.1 ± 0.2 ppm.

10 11. The crystalline Form V of any of **Claims 8 to 10** characterized by an X-ray powder diffraction pattern comprising at least one peak, which peak is at $12.5 \pm 0.1^\circ$ in 2θ .

12. The crystalline Form V of any of **Claims 8 to 10** characterized by an X-ray powder diffraction pattern comprising at least two peaks wherein one peak is $12.5 \pm 0.1^\circ$, and the second peak is selected from the group consisting of $15.8 \pm 0.1^\circ$, $16.5 \pm 0.1^\circ$, $19.1 \pm 0.1^\circ$, $19.7 \pm 0.1^\circ$, $21.5 \pm 0.1^\circ$, $25.3 \pm 0.1^\circ$, $27.7 \pm 0.1^\circ$ and $28.6 \pm 0.1^\circ$ in 2θ .

15 13. The crystalline Form V of any of **Claims 8 to 10** characterized by an X-ray powder diffraction pattern comprising at least the following peaks: $12.5 \pm 0.1^\circ$, $25.3 \pm 0.1^\circ$, $27.7 \pm 0.1^\circ$, and $28.6 \pm 0.1^\circ$ in 2θ .

20 14. The crystalline Form V of any of **Claims 8 to 10** characterized by an X-ray powder diffraction pattern comprising at least the following peaks: $12.5 \pm 0.1^\circ$, $15.8 \pm 0.1^\circ$, $16.5 \pm 0.1^\circ$, $19.1 \pm 0.1^\circ$, and $19.7 \pm 0.1^\circ$ in 2θ .

15. The crystalline Form V of any of **Claims 8 to 10** characterized by an X-ray powder diffraction pattern comprising at least the following peaks: $7.9 \pm 0.1^\circ$, $12.5 \pm 0.1^\circ$, $13.1 \pm 0.1^\circ$, $14.0 \pm 0.1^\circ$, $15.8 \pm 0.1^\circ$, $16.5 \pm 0.1^\circ$, $19.1 \pm 0.1^\circ$, $19.7 \pm 0.1^\circ$, and $25.6 \pm 0.1^\circ$ in 2θ .

25 16. The crystalline Form V of any of **Claims 8 to 10** characterized by an X-ray powder diffraction pattern comprising at least the following peaks: $7.9 \pm 0.1^\circ$, $11.2 \pm 0.1^\circ$, $12.5 \pm 0.1^\circ$, $13.1 \pm 0.1^\circ$, $14.0 \pm 0.1^\circ$, $15.8 \pm 0.1^\circ$, $19.1 \pm 0.1^\circ$, $19.7 \pm 0.1^\circ$, $20.9 \pm 0.1^\circ$, $21.5 \pm 0.1^\circ$, and $25.6 \pm 0.1^\circ$ in 2θ .

30 17. A compound that is (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone, or a salt thereof.

-36-

18. The compound of **Claim 17**, which is (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone phosphate.

19. A process for preparing a compound that is {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, comprising reacting (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone or a phosphate salt thereof with 1-azidomethyl-3,5-bistrifluoromethylbenzene in the presence of a suitable base and a solvent.

20. The process of **Claim 19** wherein the base is potassium carbonate.

21. The process of **Claim 19 or 20** wherein the solvent is selected from the group consisting of dimethylsulfoxide, isopropanol, ethanol, tetrahydrofuran, and toluene.

22. The process of **Claim 21** wherein the solvent is dimethylsulfoxide or isopropanol.

23. A process for preparing a crystalline Form IV of any of **Claims 1 to 7** comprising crystallization of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone from a solvent.

24. The process of **Claim 23** wherein the solvent is selected from the group consisting of isopropanol, acetone, acetonitrile, propanol, butanol, ethyl acetate, methyl tertiary butyl ether, and dichloromethane.

25. The process of **Claim 24** wherein the solvent is isopropanol.

26. A process for preparing a crystalline Form IV of any of **Claims 1 to 7** comprising crystallization of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone by solution-mediated phase transformation.

27. A process for preparing a crystalline form of any of **Claims 8 to 16** comprising crystallization of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone from a mixture of a solvent and an anti-solvent.

28. The process of **Claim 27** wherein the solvent is a lower alcohol.

29. The process of **Claim 28** wherein the solvent is methanol or ethanol.

30. The process of any of **Claims 27 to 29** wherein the anti-solvent is water.

-37-

31. A method for treating a condition associated with an excess of tachykinins, comprising: administering to a patient in need thereof an effective amount of the crystalline compound of any of **Claims 1 to 16**.

5 32. The method of **Claim 31** wherein the condition associated with an excess of tachykinins is selected from the group consisting of major depressive disorder, generalized anxiety disorder, social anxiety disorder, irritable bowel syndrome, and emesis.

33. The method of **Claim 32** wherein the condition is major depressive disorder.

10 34. The method of **Claim 32** wherein the condition is generalized anxiety disorder or social anxiety disorder.

35. The method of **Claim 32** wherein the condition is irritable bowel syndrome.

36. The crystalline compound of any of **Claims 1-16** for use in therapy.

15 37. Use of the crystalline compound of any of **Claims 1-16** in the manufacture of a medicament for the treatment of a disorder associated with an excess of tachykinins.

38. A pharmaceutical composition comprising a crystalline compound of any of **Claims 1 to 16**, in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents.

20 39. The composition of **Claim 38** comprising an anionic surfactant.

40. The composition of **Claim 39** wherein the anionic surfactant is sodium laurylsulfate.

41. The composition of any of **Claims 38 to 40** comprising an acid.

42. The composition of **Claim 41** wherein the acid is citric acid.

25 43. The composition of **Claim 38** comprising mannitol.

44. The composition of **Claim 38** comprising microcrystalline cellulose.

45. The composition of **Claim 38** comprising hydroxypropylcellulose.

46. The composition of **Claim 38** comprising colloidal silicon dioxide.

47. The composition of **Claim 38** comprising croscarmellose sodium.

30 48. The composition of **Claim 38** comprising stearic acid.

49. The composition of any of Claims 39 to 48 comprising crystalline Form IV {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone.